For Nano Fr0011341205 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) March 4, 2021 Regulatory News:
NANOBIOTIX (Euronext : NANO NASDAQ: NBTX - the
Company ), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. ( PharmaEngine ) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.
As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company s notification of material breach, denying a material breach of the License and Collaboration agreement, and asserting certain m ....

United Kingdom , France General , Exchange Commission On , Pharmaengine Inc , Regulatory News , Exchange Commission , Nasdaq Global Select Market , Nanobiotix Stock Exchange , Press Release , For Nano Fr0011341205 , ஒன்றுபட்டது கிஂக்டம் , பிரான்ஸ் ஜநரல் , பரிமாற்றம் தரகு ஆன் , ஒழுங்குமுறை செய்தி , பரிமாற்றம் தரகு , நாஸ்டாக் உலகளாவிய தேர்ந்தெடுக்கவும் சந்தை , ப்ரெஸ் வெளியீடு , உயிரி தொழில்நுட்பவியல் ,